文献速递病毒性肝炎

直接抗病毒药物治疗注射吸毒者或接受阿片类替代治疗者慢性丙型肝炎的疗效:系统综述与荟萃分析

Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Infect Dis · 2020-01-01

该系统综述与荟萃分析检索2010年10月至2018年3月文献,纳入11篇论文和12篇会议摘要,比较注射吸毒者(PWID)及接受阿片类替代治疗(OST)患者与对照组的丙肝治疗结局,发现OST患者合并持续病毒学应答(SVR)率为90%,PWID为88%,与对照组无显著差异,支持指南推荐治疗这些人群。

要点

  • OST患者合并SVR率为90%(95%CI 87%-93%),停药率7%(95%CI 4%-11%)。
  • PWID合并SVR率为88%(95%CI 80%-93%),停药率9%(95%CI 5%-15%)。
  • OST患者和PWID的SVR、依从性及停药率与对照组无显著差异。

核心结论

  • PWID和OST患者的HCV治疗结局与无注射吸毒史患者相似,支持当前指南推荐治疗这些人群。

研究设计与样本

  • 系统综述与荟萃分析,检索Embase、Medline、PubMed和Web of Science(2010年10月至2018年3月)。

主要发现

  • OST患者合并SVR率为90%(95%CI 87%-93%),合并停药率为7%(95%CI 4%-11%)。
  • PWID合并SVR率为88%(95%CI 80%-93%),合并停药率为9%(95%CI 5%-15%)。
  • OST患者与对照组之间、PWID与对照组之间,合并SVR率、依从性和停药率均无显著差异。
  • OST患者HCV再感染率为0.0至12.5/100人年。

临床怎么用

  • 应遵循指南推荐,对PWID和OST患者进行HCV直接抗病毒药物治疗。
  • 治疗过程中需关注停药率和再感染风险,但疗效与普通人群相当。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Treatment uptake for hepatitis C virus (HCV) infection in people who inject drugs (PWID) and patients on opioid substitution therapy (OST) is still low despite treatment guidelines that advocate the use of direct-acting antivirals (DAAs) in all patients. Our aim in this review was to investigate treatment outcomes among PWID and patients on OST in comparison to control cohorts. METHODS: A search of Embase, Medline, PubMed, and Web of Science (from October 2010 to March 2018) was conducted to assess sustained virologic response (SVR), discontinuation rates, adherence, and HCV reinfection in PWID and patients on OST. RESULTS: We identified 11 primary articles and 12 conference abstracts comprising 1702 patients on OST, 538 PWID, and 19 723 patients who served as controls. Among patients on OST, the pooled SVR was 90% (95% confidence interval [CI], 87% to 93%) and pooled treatment discontinuation rate was 7% (95% CI, 4% to 11%). Similarly, the pooled SVR was 88% (95% CI, 80% to 93%) in PWID and the pooled treatment discontinuation rate was 9% (95% CI, 5% to 15%). There was no significant difference regarding pooled rates of SVR, adherence, and discontinuation between patients on OST and controls as well as between PWID and controls. HCV reinfection rates among patients on OST ranged from 0.0 to 12.5 per 100 person-years. CONCLUSIONS: HCV treatment outcomes in PWID and patients on OST are similar to those in patients without a history of injecting drugs, supporting current guideline recommendations to treat HCV in these patient populations.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Graf C, Mücke MM, Dultz G, et al. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis. Clin Infect Dis. 2020. PMID: 31513710. doi:10.1093/cid/ciz696

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。